Navigation Links
Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
Date:10/27/2010

BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, the combined sales of seven new therapies for the treatment of breast cancer will total nearly $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Among the emerging therapies for the indication, surveyed experts are particularly enthusiastic about agents in the Poly ADP-Ribose Polymerase (PARP) inhibitor drug class.  

The Pharmacor 2010 findings from the topic entitled Breast Cancer reveal that Sanofi-Aventis's PARP inhibitor iniparib has the potential to achieve blockbuster peak-year sales in excess of $1 billion. In addition to iniparib, other key PARP inhibitors in development include AstraZeneca's olaparib and Abbott Laboratories' veliparib. Sales of agents targeting HER2-positive breast cancer will increase by almost $2 billion through 2019. This growth will be fueled by the increased uptake of Roche/Chugai's Herceptin, GlaxoSmithKline's Tykerb/Tyverb and the approval of three new HER2-targeted therapies -- Roche/Genentech/Chugai's trastuzumab-DM1, Roche/Chugai's Omnitarg and Pfizer's neratinib.

The Pharmacor 2010 findings also reveal that Roche/Genentech/Chugai's Avastin has garnered substantial patient share, particularly in the metastatic triple-negative and metastatic HR-refractory treatment settings, where effective therapies are few. However, in July 2010, Avastin's future in this indication was cast in doubt after the Oncologic Drugs Advisory Commission recommended that the FDA rescind the agent's conditional approval for first-line metastatic HER2-negative breast cancer. Additionally, Avastin's European label for breast cancer is also under review by the European Medicines Agency.

"The fact that the National Comprehensive Cancer Network guidelines panel for breast cancer recently aff
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity
2. FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL
3. Nanoelectronic transistor combined with biological machine could lead to better electronics
4. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
5. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
6. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
7. Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 -
8. Microbix Has Best-Ever Quarterly Sales
9. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
10. Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
11. Dynamic Ventures Corporation enters into a long-term agreement that brings $50 million annual sales opportunity for wholly owned subsidiary EZ-Build.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... IRVING, Texas , March 29, 2015 /PRNewswire/ ... two studies in which Caris Molecular Intelligence®, the ... molecular similarities and differences between several rare and ... treatment strategies that have the potential to improve ... Poster Session B at the Society of Gynecologic ...
(Date:3/29/2015)... March 29, 2015  Caris Life Sciences® ... in small cell cervical cancer (SCCC) that ... Intelligence®, the company,s panomic, comprehensive tumor profiling ... which may explain sensitivities and resistance to ... of certain biomarkers may guide treatment strategies ...
(Date:3/29/2015)... 2015 Caris Life Sciences® today ... showing the presence of PD-1 and PD-L1 ... Using Caris Molecular Intelligence®, the company,s panomic ... of programmed cell death protein-1 (PD-1) in ... its ligand (PD-L1) expression was variable across ...
(Date:3/29/2015)... 2015 As a symbol of its ... our pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to ... Berkenstock Race Team for the 2015 race season. Success ... but a strong sense of precision and attention to ... success in the quality control testing laboratory. Sponsorship of ...
Breaking Biology Technology:Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
... For the first time, male flies of a serious agricultural ... die whilst they are still embryos. Researchers writing in the ... of the flies that, when released into a wild population, ... of pests to be stillborn protecting important crops. , ...
... 2 Percent to $15.0 Billion; Fourth Quarter 2008 Revenue ... Share Increased 38 Percent to $3.90; Fourth Quarter 2008 ... Total Revenue Expected to be in the Range of ... to be in the Range of $4.55 to $4.75THOUSAND ...
... a global biopharmaceutical company and innovators of ERBITUX® (cetuximab), novel ... ... Wayne, PA (PRWEB) January 26, 2009 -- ... Webinar Series on February 10, 2009, 11:00-11:45 am (Eastern Standard ...
Cached Biology Technology:Gene-engineered flies are pest solution 2Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 2Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 3Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 4Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 5Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 6Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 7Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 8Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 9Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 10Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 11Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 12Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 13Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 14Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 15Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 16Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 17Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 18Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 19Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 20Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 21Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 22Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 23Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 24Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 25Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 26Amgen's Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55 27MODA Offers Paperless QC Micro Webinar Series on Automating Environmental Monitoring, Utility and Product Testing 2MODA Offers Paperless QC Micro Webinar Series on Automating Environmental Monitoring, Utility and Product Testing 3
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... of the "Global Iris Recognition Market 2015-2019" ... the Global Iris Recognition market to grow at a ... This report covers the present scenario and the ... the period 2015-2019. To calculate the market size, the ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... October 1, 2009, Bethesda, MarylandA $2.5 million "stimulus ... (NIH) will enable the American Society for Cell Biology ... the cell that will be readily accessible to researchers, ... Director Joan Goldberg. "We are very ...
... industry and academia will meet at McGill University, in Montreal, ... security in the world. The 2nd McGill Conference on Global ... economic crisis on food supply and production. In the ... the ranks of the roughly 1 billion people worldwide considered ...
... (CHICAGO - Sept. 30, 2009) U.S. Environmental Protection Agency,s ... of a dioxin exposure study conducted by the University ... the study was conducted well and provided useful, scientifically ... to help EPA fully evaluate human exposure to levels ...
Cached Biology News:ASCB wins NIH 'stimulus grant' to build virtual library of cell images for researchers and public 2EPA reviews Univ. of Michigan dioxin study 2
... • Enzyme concentration - 5 units/µL ... in higher yields ,• Leaves an 'A' ... DNA polymerase which exhibits very high activity ... applications. To ensure the quality of the ...
... GCpro Taq DNA Polymerase is a ... advantages for all PCR applications. GCpro Taq ... clone expressed in E. coli, containing the ... The enzyme includes a highly processive 5'-3' ...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
... Reduce bench time to just 15 minutes! ... the paralles that can be drawn between this ... idea of instant foods. Instant meals consumed ... freeze-dried format and are reconstituted by adding water. ...
Biology Products: